Rein Therapeutics, Inc.
RNTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001420565
No open-market purchases or sales by Rein Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $42.3M in total; no superinvestor holds it.
Holders of 5% or more of RNTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Rein Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Voss Capital, LLC | 13G/A | 11.30%2.67M shares | +5.70 ppfrom 5.60% | May 14, 20252 filings | Sep 26, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Rein Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Sep 26, 20256:46 PM ET | Voss Capital, LLCand 4 others | 13G/A | 11.30%2.67M shares | +5.70 ppfrom 5.60% | Sep 24, 2025 | SEC |
| May 14, 20258:26 PM ET | Voss Capital, LLCand 4 others | 13G | 5.60%1.28M shares | New | May 8, 2025 | SEC |
| Nov 5, 20245:17 PM ET | University of Texas/Texas Am Investment Managment Coand 1 other | 13G/A | 4.40%960.7K shares | –Below 5% | Nov 4, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Rein Therapeutics, Inc. shares.
No Form 144 notices for Rein Therapeutics, Inc. are on file.